Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

Jun 1, 2025 - 17:00

0

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

Related Posts

The five keys to unlock homeownership for emerging buyers

The five keys to unlock homeownership for emerging buyers

Mar 21, 2025 0

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Target Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - TGT

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Target Corp...

Mar 21, 2025 0

DOGE says IRS modernization program is $15B over budget and 30 years overdue

DOGE says IRS modernization program is $15B over budget...

Mar 21, 2025 2

Businesses may have to pass high beef prices on to consumers

Businesses may have to pass high beef prices on to cons...

Mar 21, 2025 0

JPMorgan rebrands diversity program

JPMorgan rebrands diversity program

Mar 21, 2025 4

Meta global affairs chief says decision not to offer Instagram, Facebook in China helps defend free expression

Meta global affairs chief says decision not to offer In...

Mar 21, 2025 2